BCM
FBRX icon

BML Capital Management’s Forte Biosciences FBRX Stock Holding History

BML Capital Management’s Portfolio FBRX Stock Details FBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-70,468
Closed -$394K – 28
2024
Q3 		$394K Hold
70,468
– – 0.23% 26
2024
Q2 		$946K Hold
70,468
– – 0.68% 22
2024
Q1 		$1.23M Hold
70,468
– – 0.81% 21
2023
Q4 		$1.45M Hold
70,468
– – 1.1% 18
2023
Q3 		$1.17M Buy
70,468
+1,065
+2% +$23.6K 1.07% 14
2023
Q2 		$1.8M Hold
69,403
– – 1.62% 15
2023
Q1 		$1.75M Buy
69,403
+10,948
+19% +$275K 1.51% 19
2022
Q4 		$1.46M Buy
+58,455
New +$1.5M 1.4% 17

Other funds holding FBRX

FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

BML Capital Management's FBRX Position: Q4 2024 in Review

BML Capital Management sold out of Forte Biosciences (FBRX) in Q4 2024, closing a stake of 70,468 shares — an estimated $394K sold.

BML Capital Management first reported a position in FBRX in Q4 2022 and held it in 8 quarters. The position peaked at $1.8M in Q2 2023. 26 funds tracked by Wall St. Rank hold FBRX as of Q4 2024.

  • BML Capital Management reported no remaining Forte Biosciences position as of Q4 2024 after selling out during the quarter.
  • BML Capital Management sold 70,468 Forte Biosciences shares in Q4 2024, an estimated $394K.
  • BML Capital Management first reported a position in Forte Biosciences in Q4 2022 and held it in 8 quarters.
  • BML Capital Management's Forte Biosciences position peaked at $1.8M in Q2 2023.
  • 26 funds tracked by Wall St. Rank held Forte Biosciences as of Q4 2024.

Based on BML Capital Management's 13F filing for Q4 2024, filed 7 Feb 2025.